Sp-cAMPS
目录号 : GC61747
Sp-cAMPS，一种cAMP类似物，是一种依赖cAMP的PKAI和PKAII的有效激活剂。Sp-cAMPS还是一种有效的竞争性磷酸二酯酶(PDE3A)抑制剂，Ki为47.6µM。Sp-cAMPS以EC50为40μM来结合PDE10GAF域。
Cas No.:71774-13-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM[1][2][3].
Treatment of hepatocytes with Sp-cAMPS, the stimulatory diastereomer of adenosine cyclic 3',5'-phosphorothioate, mimics the response seen with glucagon. The glucagon-stimulated increases in the level of Ca2+ can be mimicked by Sp-cAMPS[4].
In chronic alcohol consumption (CAC) mice, direct infusion of the Sp-cAMPS (1 µg/µL) into the prefrontal cortex significantly improves or impairs, respectively, working memory performance in withdrawn and water animals[5].
[1]. Su H Hung, et al. A new nonhydrolyzable reactive cAMP analog, (Sp)-adenosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase. Bioorg Chem. 2002 Feb;30(1):16-31. [2]. L Y Wang, et al. Regulation of kainate receptors by cAMP-dependent protein kinase and phosphatases. Science. 1991 Sep 6;253(5024):1132-5. [3]. Ronald JÄger, et al. Activation of PDE10 and PDE11 phosphodiesterases. J Biol Chem. 2012 Jan 6;287(2):1210-9. [4]. P A Connelly,et al. A study of the mechanism of glucagon-induced protein phosphorylation in isolated rat hepatocytes using (Sp)-cAMPS and (Rp)-cAMPS, the stimulatory and inhibitory diastereomers of adenosine cyclic 3',5'-phosphorothioate. J Biol Chem. 1987 Mar 25;262(9):4324-32. [5]. G Dominguez, et al. Rescuing prefrontal cAMP-CREB pathway reverses working memory deficits during withdrawal from prolonged alcohol exposure. Brain Struct Funct. 2016 Mar;221(2):865-77.
| Cas No. | 71774-13-5 | SDF | |
| Canonical SMILES | O[C@H]1[C@@H](O[C@@]2([H])[C@@]1([H])O[P@](OC2)(S)=O)N3C4=C(C(N)=NC=N4)N=C3 | ||
| 分子式 | C10H12N5O5PS | 分子量 | 345.27 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8963 mL | 14.4814 mL | 28.9628 mL |
| 5 mM | 0.5793 mL | 2.8963 mL | 5.7926 mL |
| 10 mM | 0.2896 mL | 1.4481 mL | 2.8963 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet